Open AccessDopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine
Author(s) -
M Doknic,
Sandra Pekić,
Miloš Žarković,
Milica MedicStojanoska,
Carlos Diéguez,
Felipe F. Casanueva,
V. Popovic
Publication year - 2002
Publication title -
european journal of endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.897
H-Index - 148
eISSN - 1479-683X
pISSN - 0804-4643
DOI - 10.1530/eje.0.1470077
Subject(s) - medicine , bromocriptine , endocrinology , prolactin , leptin , dopaminergic , body mass index , hyperprolactinaemia , prolactinoma , obesity , dopamine agonist , hormone , dopamine
It has recently been shown that increased body weight is associated with prolactinomas and that weight loss occurs with normalization of prolactin levels. On the other hand, decreased dopaminergic tone in humans is well correlated with obesity. The objective of this study was to correlate changes in prolactin levels with leptin and body mass index (BMI) in patients with prolactinomas treated with the long-acting dopamine agonist bromocriptine (BC).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom